sipuleucel-T (Provenge)
Jump to navigation
Jump to search
Indications
Procedure
- leukapheresis
- in vitro stimulation to a protein found in most prostate cancer cells linked to an adjuvant
- the stimulated leukocytes are returned to the patient
- 3 doses at 1 week intervals
Mechanism of action
- autologous cellular immunotherapy
Notes
- cost (2010) $93,000 compared with $18,000 for docetaxel
- increases life expectancy from 22 to 26 months
More general terms
References
- ↑ Prescriber's Letter 17(6): 2010 Provenge (Sipuleucel-T) for Advanced Prostate Cancer Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260612&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Nelson R onger Survival With Sipuleucel-T in Advanced Prostate Cancer. Medscape - Nov 09, 2020 https://www.medscape.com/viewarticle/940590
McKay RR, Hafron JM, Ferro C et al A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. Adv Ther 2020. 37, 4910-4929 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33029725 PMCID: PMC7596004 Free PMC article https://link.springer.com/article/10.1007/s12325-020-01509-5